Relmada Therapeutics (RLMD) Tops Q4 EPS by 3c

Relmada Therapeutics (NASDAQ: RLMD) reported Q4 EPS of ($1.80), $0.03 better than the analyst estimate of ($1.83).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• Valens Semiconductor (VLN) Reports In-Line Q2 EPS, Misses on Revenue; Offers FY26 Revenue Guidance
• New York City REIT Inc. (NYC) Reports Q2 Loss of $3.04
• Lightwave Logic, Inc. (LWLG) Reports Q2 Loss of $0.04